Remogliflozin etabonate is the ester prodrug of remogliflozin, a selective sodium-dependent glucose cotransporter-2 inhibitor. This work investigated the absorption, metabolism, and excretion of [ A ketoconazole clinical drug interaction study, along with the human mass balance findings, confirmed that CYP3A4 contributes less than 50% to remogliflozin metabolism, demonstrating that other enzyme pathways (e.g., P450s, UDP-glucuronosyltransferases, and glucosidases) make significant contributions to the drug's clearance. Overall, these studies support a low clinical drug interaction risk for remogliflozin etabonate due to the availability of multiple biotransformation pathways.
Introduction
The human solute carrier 5 family comprises 12 genes, including members of the sodium-dependent glucose cotransporter (SGLT) family (Wright, 2001; Wright and Turk, 2004; Jabbour and Goldstein, 2008) . SGLT1 is a high-affinity, low-capacity glucose/galactose cotransporter that is primarily expressed in the intestine but that is also present in the kidney (Nishimura and Naito, 2005; Bakris et al., 2009 ). In contrast, SGLT2 is a low-affinity, high-capacity glucose transporter that is selectively expressed in the kidney. Together, SGLT1 and SGLT2 are responsible for the active reabsorption of glucose across Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.
http://dx.doi.org/10.1124/dmd.112.047258.
ABBREVIATIONS:
SGLT, sodium-dependent glucose cotransporter; GSK, GlaxoSmithKline; GSK189075, 5-methyl-1-(1-methylethyl)-4-({4- GSK355993, oxy]phenyl}methyl)-1H-pyrazol-3-yl-␤-D-glucopyranosiduronic acid; MDR, multidrug resistance; HLM, human liver microsomes; AE, adverse event; LC-MS/MS, liquid chromatography-tandem mass spectrometry; LC, liquid chromatography; MS, mass spectrometry; MS/MS, tandem mass spectrometry; AUC (0-ϱ) , area under the concentration-time profile from zero time to infinity; CI, confidence interval; HPLC, high-performance liquid chromatography; MDCKII, Madin-Darby canine kidney II; GF120918, N-[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl] phenyl]-5-methoxy-9-oxo-10H-acridine-4-carboxamide.
the renal luminal membrane (Wright and Turk, 2004; Idris and Donnelly, 2009) . Once reabsorbed by the renal epithelial cell, glucose is transported to the blood by facilitated diffusion via sodium-independent glucose transporters. The uptake of glucose in the proximal tubules by SGLT1 and SGLT2 is highly efficient, resulting in complete reabsorption. The importance of the SGLT transporters in intestinal and renal glucose absorption is evident from individuals with mutations in the genes encoding for SGLTs. SGLT1 deficiency leads to glucose-galactose malabsorption syndrome, which results in severe, sometimes fatal, diarrhea (Turk et al., 1991; Wright and Turk, 2004) . In contrast, genetic alterations in SGLT2 result in increased renal glucose excretion with no apparent adverse effects on carbohydrate metabolism (van den Heuvel et al., 2002; Washburn, 2009 ). Therefore, on the basis of the observation of glucosuria in subjects genetically deficient in SGLT2 activity, the SGLT2 transporter is currently a target of therapeutic interest for the treatment of diabetes and obesity (Bays, 2009; Papazafiropoulou et al., 2011; Washburn, 2012) . Remogliflozin etabonate (GSK189075; 5-methyl-1-(1-methylethyl)-4-({4-[(1-methylethyl)oxy]phenyl}methyl)-1H-pyrazol-3-yl-6-O- [(ethyloxy) carbonyl]-␤-D-glucopyranoside) is the prodrug of remogliflozin (GSK189074; 5-methyl-1-(1-methylethyl)-4-({4-[(1-methylethyl)oxy] phenyl}methyl)-1H-pyrazol-3-yl-␤-D-glucopyranoside), the active entity that inhibits SGLT2 ( Fig. 1) (Fujimori et al., 2008) . Remogliflozin etabonate causes a concentration-dependent increase in urinary glucose excretion in humans and nonclinical species Dobbins et al., 2012) . Oral administration of remogliflozin etabonate reduces postprandial glucose excursions without inducing hypoglycemia, improves plasma glucose concentrations in subjects with diabetes, and reduces glycosylated hemoglobin (HbA1c) levels. SGLT2 inhibitors such as remogliflozin etabonate have the potential to be used in the treatment of type 2 diabetes mellitus as monotherapy and/or in combination with existing therapies and may also have potential efficacy as a weight-loss agent (Papazafiropoulou et al., 2011) . This work investigated the absorption, metabolism, and excretion of [ 14 C]remogliflozin etabonate in humans and the influence of Pglycoprotein (Pgp) and cytochrome P450 (P450) enzymes on the disposition of remogliflozin etabonate and its metabolites to understand the risks for drug interactions. These clinical and in vitro studies have characterized the role of metabolic enzymes and transporters involved in remogliflozin etabonate disposition, providing a mechanistic basis for predicting potential clinical drug interactions. (Fig. 1) . GlaxoSmithKline Chemical Development (Stevenage, UK) supplied remogliflozin etabonate, remogliflozin, 5-me- tained from XenoTech, LLC (Lenexa, KS). Alamethicin, UDP-glucose dehydrogenase (type VI) from bovine liver and ␤-glucosidase from almond were obtained from Sigma-Aldrich (St. Louis, MO). Transwell 12-well multiwell inserts with polycarbonate membranes (0.4-M pore size, 1.1-cm 2 surface area) were obtained from Corning Life Sciences (Lowell, MA). All other chemicals and solvents were obtained from commercial suppliers and were of analytical grade or higher.
Materials and Methods

Materials
Clinical Study Designs. All clinical studies were approved by their investigational review committees and were conducted according to principles of good clinical practice and the Declaration of Helsinki. All subjects underwent an initial screening assessment after collection of written informed consent. The screening assessment was conducted within 28 days of the first dose and included a medical history, physical examination, and medical and laboratory evaluations such as 12-lead electrocardiography, drug screen, and pregnancy test (females). Exclusion criteria included a positive drug or alcohol test, past or current history of excessive alcohol or illicit drug use, recent participation in another research trial (i.e., within 30 days before screening), use of any prescription or nonprescription drugs, vitamins, herbal and dietary supplements, or grapefruit-containing products within 14 days or five half-lives before the start of the dosing phase of the clinical study, regular use of tobaccoor nicotine-containing products within 3 months of screening visit, and any pre-existing conditions that would interfere with normal gastrointestinal anatomy or motility or hepatic and/or renal function.
The human mass balance clinical study was an open-label, single-dose study conducted with eight healthy, nonsmoking males. The mean age was 42.1 years with a range of 31 to 54 years. All subjects completed the study. The in-life portion of this study was conducted at the Covance Clinical Research Unit, Inc. (Madison, WI). The study protocol was registered with the National Institutes of Health clinical trials database with identifier NCT00501683. Fasted subjects received three capsules by mouth that contained a total of 402 Ϯ 1.0 mg of [ 14 C]remogliflozin etabonate (106 Ϯ 0.3 Ci; specific activity, 0.27 Ci/mg) as a solution prepared in Acconon MC-8 (Abitec Corporation, Columbus, OH). Blood samples (7 ml) were collected in tubes containing potassium oxalate and sodium fluoride at times 0 (immediately before dosing), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36 , and 48 h. A portion of whole blood (1 ml) was removed from each sample for the determination of blood radioactivity, and the remainder was processed to provide plasma for pharmacokinetic analysis. Additional blood samples (40 ml each) were collected at 1, 4, 12, and 24 h after dosing and were processed to provide plasma for metabolite profiling and structural identification. Urine was collected before dosing, at 0 to 6, 6 to 12, and 12 to 24 h after dosing, and at 24-h intervals through 144 h after dosing. Urine was stored at 2 to 8°C during collection and subsequently frozen at Ϫ70°C or lower. Feces were collected before dosing and at 24-h intervals through 144 h after dosing and were stored frozen at Ϫ70°C or lower. Three adverse events (AEs) were reported in two subjects during the study: diarrhea, headache, and ecchymosis. No AEs were considered to be drug-related. All three AEs were mild in intensity and resolved within 2 to 10 days.
The ketoconazole drug interaction study was a single-center phase I study conducted at Ohio State University (Columbus, Ohio). The study protocol was registered with the National Institutes of Health clinical trials database with identifier NCT00501397. A maximum of 22 healthy male and female subjects were to be enrolled to ensure completion of at least 16 evaluable subjects. This was an open-label, single-sequence study to investigate the effect of ketoconazole (repeat 400 mg once daily for 6 days) on the pharmacokinetic profile of remogliflozin etabonate (single 250-mg dose). The study consisted of three treatment sessions. Session 1 was a 24-h inpatient sampling period after a single dose of remogliflozin etabonate. Session 2 was a 4-day outpatient period with 400 mg of oral ketoconazole administered once daily to achieve steadystate plasma concentrations. Subjects returned to the clinic for session 3 and received their daily dose of ketoconazole administered by study staff on days 5 and 6. Session 3 was a 48-h inpatient sampling period conducted after a single dose of remogliflozin etabonate administered with ketoconazole on day 5. Subjects were to avoid food for at least 8 h before dosing for both remogliflozin etabonate and ketoconazole. Serial blood (2 ml) samples were collected in tubes containing potassium oxalate and sodium fluoride at times 0 (immediately before dosing), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36 , and 48 h on day 1 of session 1 and on days 5 and 6 of session 3 for the determination of remogliflozin etabonate, remogliflozin, GSK279782, and GSK333081 concentrations in plasma.
Of the 20 subjects enrolled in the ketoconazole study, 19 subjects (95%) completed. The mean age was 39 years with a range of 22 to 55 years. Seventeen subjects (85%) were male and three were female (15%). Only one AE, epistaxis, was reported during session 1 when remogliflozin etabonate was administered alone. All other AEs occurred when ketoconazole was administered either alone (headache, nausea, eye pain) or in combination with remogliflozin etabonate (headache, nausea, vomiting, contusion, postprocedural complication, sinus congestion, and furuncle). No serious AEs were reported, and no subject discontinued study medication or was withdrawn prematurely from the study as a result of an AE. No clinically meaningful treatment-related changes in mean chemistry or hematology values were observed during the study. No clinically relevant changes in electrocardiographic parameters were observed, and vital sign measurements were relatively stable.
Quantification of Radioactivity. Radioactivity in blood, plasma, urine, and feces was quantified by liquid scintillation counting using a 2900TR liquid scintillation counter (PerkinElmer Life and Analytical Sciences). Duplicate aliquots of plasma (0.3 ml) and triplicate aliquots of urine (1 ml) were mixed directly with Ultima Gold scintillation cocktail before analysis (PerkinElmer Life and Analytical Sciences). Feces were mixed with 50% ethanol in deionized water (approximately 3:1 volume ethanol/water to wet-weight feces) and were homogenized. Duplicate aliquots of blood (0.3 ml) and triplicate aliquots of fecal homogenate (0.3 g) were combusted using a model 307 Sample Oxidizer (PerkinElmer Life and Analytical Sciences). The resulting 14 CO 2 was trapped in Carbo-Sorb (PerkinElmer Life and Analytical Sciences), mixed with Permafluor scintillation cocktail (PerkinElmer Life and Analytical Sciences), and analyzed. The total radioactivity in blood and plasma is reported as nanogram-equivalents remogliflozin etabonate per ml. Radioactivity in the urine and feces is reported as a percentage of the administered dose per time period. The percentage of radioactivity associated with blood cells was calculated according to the equation 100 Ϫ [(C p )(1 Ϫ Hct)/(C b ) ϫ 100], where C p and C b are the concentrations of radioactivity in plasma and blood, respectively, and Hct is the hematocrit. The blood/plasma ratio was calculated as C b /C p .
Quantification of Remogliflozin Etabonate and Metabolites in Plasma. The plasma concentrations of remogliflozin etabonate, remogliflozin, GSK279782, and GSK333081 were measured by using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. In brief, a 50-l aliquot of plasma was added to 200 l of acetonitrile containing [ 2 H 7 ]-labeled internal standards of each analyte and was vortex-mixed. The samples were centrifuged at 1200g for 5 min, and 150 l of the supernatants was removed and dried under warm nitrogen. Samples were reconstituted in 75 l of water containing 20% acetonitrile (v/v) and 0.1% formic acid (v/v), and 5 l was injected onto an LC-MS/MS system consisting of a MDS Sciex 3000 (Applied Biosystems/MDS Sciex, Foster City, CA) equipped with a CTC HTS PAL autosampler (Leap Technologies, Carrboro, NC), a Shimadzu 10AD solvent delivery system (Shimadzu Scientific Instruments Inc., Columbia, MD), and a Varian Polaris C-8-Ether column (50 ϫ 2.0 mm, 3 m; Varian, Inc., Palo Alto, CA). Mobile phase A consisted of 0.1% formic acid in water (v/v), and mobile phase B consisted of 0.1% formic acid in methanol. The gradient started at 40% B and increased linearly to 50% B from 0 to 0.6 min, to 60% B from 0.6 to 0.9 min, and to 90% B from 0.9 to 1.2 min. The gradient was held at 90% B from 1.2 to 1.8 min and returned to 40% B from 1.8 to 2.5 min. The analyses were performed at room temperature at a flow rate of 0.4 ml/min. LC-MS/MS analysis was conducted using a TurboIonSpray interface (Applied Biosystems/MDS Sciex) operated in the positive-ion mode and a probe temperature of 450°C. The analytes were measured by multiple reaction monitoring of the following [M ϩ H] ϩ transitions: remogliflozin etabonate, m/z 523 3 289; remogliflozin, m/z 451 3 289; GSK279782, m/z 409 3 247; and GSK333081, m/z 409 3 247. The transitions monitored for the internal standards were seven mass units higher than those of the corresponding analytes. Data collection and integration were performed using Analyst software (Applied Biosystems/MDS Sciex). Quantification was based on analyte/ internal standard peak area ratios and calculated using a weighted 1/x 2 linear regression model with SMS2000 (version 2.0; GlaxoSmithKline, Research Triangle Park, NC). The operating range of the assay was 1 to 1000 ng/ml for remogliflozin etabonate, GSK279782, and GSK333081 and was 2 to 1000 ng/ml for remogliflozin.
Pharmacokinetic Analysis of Remogliflozin Etabonate and Metabolites in Plasma.
The plasma pharmacokinetic parameters were estimated by noncompartmental methods with WinNonlin version 4.1 (Pharsight, Mountain View, CA) using actual pharmacokinetic sampling times. The maximal observed drug concentration (C max ) and the time of its occurrence (t max ) were taken directly from the concentration-time profile. The area under the concentration-time profile from 0 time to infinity (AUC (0-ϱ) ) was calculated using the linear-up/logarithmic-down trapezoidal method [AUC (0-last) ] and extrapolation to infinite time by the addition of C last / z , where z is the apparent terminal phase elimination rate constant estimated by linear regression of the logarithmically transformed concentration data. A minimum of three terminal-phase concentration values were used to estimate z . Sampling of blood and plasma for total radioactivity and specific analytes was done through 48 h. Concentrations of radioactivity were below limits of quantitation (125 and 119 ng Eq/ml for blood and plasma, respectively) by 36 h in all subjects. The mean percentage area under the concentration-time curve extrapolated to infinity for total radioactivity in blood and plasma were 8 and 10%, respectively (minimum, 4 and 6%; and maximum, 22 and 20%). All the analytes determined by liquid chromatography (LC)/mass spectrometry (MS) had percentage area under the concentration-time curve extrapolated to infinity values that were less than 5%.
Statistical Analyses. Statistical analyses were performed with SAS (version 8.2; SAS Institute, Cary, NC). The geometric mean and 95% confidence intervals (CIs) were calculated for each pharmacokinetic parameter, except t max for which median and range were calculated. Estimation of the effect of ketoconazole on AUC (0-ϱ) , C max , and t 1/2 of remogliflozin, GSK279782, and GSK333081; and area under the concentration-time profile from zero time to time t, C max , and t 1/2 of remogliflozin etabonate was conducted with remogliflozin etabonate alone as the reference treatment. A mixed-effect model with log e (pharmacokinetic parameter) as the dependent variable, a fixed effect for treatment, and a random effect for subject was used to estimate treatment difference on the log e scale. The PROC MIXED from SAS (version 8.2; SAS Institute) was used to fit the model. The effect of coadministration of ketoconazole with remogliflozin etabonate was estimated by exponentiating the difference in least-squares means [(remogliflozin etabonate ϩketoconazole) Ϫ remogliflozin etabonate alone] and the corresponding 90% CI to obtain the point estimate and CI for the ratio of geometric means. T max for all analytes was analyzed nonparametrically, with point estimates and 90% CIs for the median differences of t max between treatments calculated using the HodgesLehmann method (Hauschke et al., 1990) .
Sample Preparation for Metabolite Profiling. Plasma. Equal volumes of plasma were pooled from each subject by time point to produce representative 1, 4, 12, and 24 h postdose samples. Pooled plasma samples (1-6 ml) were extracted by adding 1 volume of methanol, followed by 2 volumes of acetonitrile, vortex mixing after each addition. Samples were centrifuged at 2400g for 5 min, and the supernatants were transferred to clean tubes. The pellets were extracted again with methanol and acetonitrile, and the supernatants were pooled with the initial extracts. Varying amounts of each extract (4.5-11.4 ml) were dried under nitrogen and reconstituted in 400 to 750 l of water/100 mM ammonia acetate (pH 5.0)/acetonitrile (8.5:1:0.5, v/v/v). The samples were centrifuged, and portions of the supernatants (200 -400 l) of each extract were profiled.
Urine. Urine was pooled proportionally by sample weight to produce a single 0 to 48-h sample for each subject. Pooled urine was centrifuged at 21,000g for 5 min, and a portion (250 l) of each supernatant was profiled.
Metabolite Profiling. Plasma and urine radiochromatograms were generated by using an HP-1100 high-performance liquid chromatography (HPLC) system (Agilent Technologies, Santa Clara, CA) with a Pursuit C-18 column (4.6 ϫ 250 mm, 5 m; Varian, Inc.). Mobile phase A consisted of water/100 mM ammonia acetate (pH 5.0)/acetonitrile (8.5:1:0.5, v/v/v), and mobile phase B consisted of water/100 mM ammonia acetate (pH 5.0)/acetonitrile (0.5:9:0.5, v/v/v). The gradient started at 0% B and increased linearly to 5% B from 0 to 20 min, to 6% B from 20 to 30 min, to 17% B from 30 to 60 min, to 18% B from 60 to 70 min, to 30% B from 70 to 95 min, to 45% B from 95 to 105 min, and to 80% B from 105 to 110 min. The gradient was held at 80% B for 5 min and returned to initial conditions at 115.1 min. The column was allowed to equilibrate for 15 min between injections. The analyses were performed at 45°C and a flow rate of 1 ml/min. Online radiochemical detection was performed using a Flo One radio flow detector (PerkinElmer Life and Analytical Sciences) and Ultima Flo M scintillation fluid at a flow rate of 3 ml/min. When necessary, offline radiochemical detection was performed by collecting column fractions into Deepwell LumaPlate 96-well plates (PerkinElmer Life and Analytical Sciences). The plates were dried under a stream of nitrogen and analyzed on a TopCount NXT microplate scintillation counter (PerkinElmer Life and Analytical Sciences). Radiochemical profiles generated online were integrated by using Flo One for Windows software (version 3.65). The limit of detection for online analysis was set to three times background, and the lower limit of quantification was 500 cpm. For offline analysis, TopCount data were imported into Excel (Microsoft, Redmond, WA), and peak areas were calculated. The limit of detection and quantification for offline analysis were set to two times background. Profiling data were subsequently imported into Laura Radio HPLC software (LabLogic Systems, Inc., Sheffield, UK) for presentation purposes.
In vitro samples generated to determine the pathway of GSK1997711 formation were analyzed using online radiochemical detection in a fashion similar to plasma-to-urine analysis, except that the gradient started at 15% B and increased linearly to 80% from 0 to 40 min. The gradient was held at 80% B for 5 min and returned to initial conditions at 45.1 min. The column was allowed to equilibrate for 15 min between injections.
In vitro P450 phenotyping samples were analyzed using online radiochemical detection with an Agilent Zorbax Eclipse XDB-C8 column (150 ϫ 150 mm, 5 m; Agilent Technologies). Mobile phase A consisted of 5 mM ammonium acetate in 5% acetonitrile (v/v) and 5 mM ammonium acetate in 95% acetonitrile (v/v). The gradient started at 0% B and increased linearly to 23% B from 0 to 50 min, to 33% from 50 to 57 min, and to 100% B from 57 to 60 min. The gradient was held at 100% B from 60 to 65 min and returned to initial conditions from 65 to 67 min. The column was allowed to equilibrate for 8 min between injections. The analyses were conducted at ambient temperature and a flow rate of 1 ml/min.
Metabolite Identification. [ 14 C]Remogliflozin metabolites in plasma and urine were identified by MS analysis of fractions collected after separation by using the HPLC method described for metabolite profiling. Reconstructed radiochromatograms were used to link metabolites characterized from the liquid chromatography eluent in 96-well plates to peaks in quantitative profiles. A Waters quadrupole time-of-flight mass spectrometer (Waters, Milford, MA) with an Advion nanoelectrospray source (Advion, Inc., Ithaca, NY) operating in positive-ion mode was used to collect MS and tandem mass spectrometry (MS/MS) data on quantifiable metabolites. Experimental parameters included a cone potential of 40 V, source temperature of 90°C, and argon collision gas. Collision energies were ramped during infusion and were selected on the basis of desired fragmentation. Leucine enkephalin (ϳ0.1-0.2 g/ml) was used for full mass range acquisition accurate mass measurements, using known fragment ions as lock masses. The structural characterization of remogliflozin etabonate metabolites by nanoelectrospray mass spectral analysis was simplified by assessing MS/MS fragmentation and noting structural changes to the glucose residue, the pyrazole, or the phenyl isopropyl ether group. A comparison of chromatographic retention time, accurate mass of the protonated molecular ion [M ϩ H] ϩ , and MS/MS fragmentation of synthetic standards was used to characterize the majority of metabolites. The structural characterization of M13 was confirmed using a combination of 1 H nuclear magnetic resonance experiments (H-1D, total correlation spectroscopy, and nuclear Overhauser effect spectroscopy), MS (accurate mass and MS/MS), and comparison of the accurate mass of the protonated molecular ion [M ϩ H]ϩ and MS/MS fragmentation with GSK333081 [GlaxoSmithKline (GSK) data on file].
Identification of P450 Enzymes Involved in the Metabolism of Remogliflozin. A 1:1 blend of unlabeled and 14 C-labeled remogliflozin (50 M) was incubated in duplicate with HLM (2 mg/ml) or Cypex Bactosomes (150 pmol/ml; Cypex Ltd.) containing recombinantly expressed CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 for 2 h at 37°C. The reaction mixture consisted of phosphate buffer (50 mM, pH 7.4) and an NADPH-regenerating system (0.44 mM ␤-NADP, 5.5 mM glucose 6-phosphate, and 1.2 units of glucose-6-phosphate dehydrogenase) in a final volume of 500 l. The reactions were terminated by the addition of 500 l of acetonitrile followed by centrifugation, and a 25 to 50-l portion of each supernatant was profiled for metabolites, as described under Metabolic Profiling. The rates of metabolite production by the expressed P450 enzymes were dmd.aspetjournals.org normalized with respect to the content of the corresponding P450 in pooled HLM (Rodrigues, 1999) . To confirm the enzymes involved, inhibition studies were conducted using HLM as described previously in the presence or absence of the selective P450 inhibitors azamulin (CYP3A4, 1 M) (Stratton et al., 2000; Stresser et al., 2004) , sulfaphenazole (CYP2C9, 10 M) (Baldwin et al., 1995) , quinidine (CYP2D6, 1 M) (Otton et al., 1988) , montelukast (CYP2C8, 1 M) (Walsky et al., 2005) , furafylline (CYP1A2, 1 M) (Sesardic et al., 1990) , and benzylnirvanol (CYP2C19, 5 M) (Suzuki et al., 2002) . Incubations containing azamulin and furafylline were preincubated at 37°C for 10 min in the presence of microsomes and the NADPH-regenerating system before the addition of [
14 C]remogliflozin. The remaining inhibitors were preincubated at 37°C for 5 min in the presence of microsomes and [
14 C]remogliflozin. All P450 phenotyping reactions were initiated by the addition of the NADPH-regenerating system.
Identification of the Pathway of GSK1997711 Formation. A role for UDP-glucose dehydrogenase in the direct conversion of remogliflozin to GSK1997711 through oxidation of the C6 hydroxyl group of the glucose group to glucuronic acid was investigated using human liver cytosol and purified UDP-glucose dehydrogenase. Human liver cytosol (1 mg/ml) and a 1:1 blend of unlabeled and 14 C-labeled remogliflozin (50 M) were incubated in duplicate at 37°C in a reaction mixture consisting of potassium phosphate buffer (100 mM, pH 7.4) and NADϩ (2 mM) in a final volume of 1 ml. Portions (300 l) were removed at t ϭ 0 and 1 h, added to an equal volume of acetonitrile, and centrifuged, and the supernatants were profiled. Purified UDP-glucose dehydrogenase (3.8 units/ml) and a 1:1 blend of unlabeled and 14 C-labeled remogliflozin (5 M) were incubated in duplicate at 37°C in a reaction mixture consisting of Tris-HCl (50 mM, pH 8.7), dithiothreitol (5 mM), and NADϩ (2 mM) in a final volume of 1 ml. Control incubations were performed without NADϩ. Portions (300 l) were removed at various times up to 4 h, added to an equal volume of acetonitrile, and centrifuged, and the supernatant was profiled.
The formation of GSK1997711 through glucuronidation of the aglycone of remogliflozin (GSK1132678) was investigated 1) by incubating [
14 C]remogliflozin with human liver S9 supplemented with glucuronidation reagents and 2) by incubating [
14 C]remogliflozin with ␤-glucosidase to produce the aglycone, followed by incubation with HLM and glucuronidation reagents. Incubations with liver S9 (1 mg/ml) and a 1:1 blend of unlabeled and 14 C-labeled remogliflozin (50 M) were performed in duplicate at 37°C in a reaction mixture consisting of potassium phosphate buffer (100 mM, pH 5.5 or 7.4), MgCl 2 (5 mM), alamethicin (0.025 mg/ml), and UDP-GlcUA (2 mM) in a volume of 1 ml. Portions (300 l) were removed at various times up to 2 h, added to an equal volume of acetonitrile, and centrifuged, and the supernatants were profiled. Incubations with purified ␤-glucosidase (5.25 units/ml) and 1:1 blend of unlabeled and 14 C-labeled remogliflozin (5 M) were performed in duplicate at 37°C in potassium phosphate buffer (100 mM, pH 5.5) in a final volume of 1 ml. Portions (100 l) were removed at various times up to 2 h, added to an equal volume of acetonitrile, and analyzed as above to confirm formation of the GSK1132678 aglycone. At the 2-h time point, an additional portion (328 l) was removed from each incubation and 40 l of Tris-HCl (1M, pH 8.7) was added, followed by the addition (in a final volume of 400 l) of pooled HLM (1 mg/ml), MgCl 2 (5 mM), alamethicin (0.025 mg/ml), and UDP-GlcUA (2 mM). Portions (100 l) were removed at t ϭ 0 and 1 h, added to an equal volume of acetonitrile, and centrifuged, and the supernatants were profiled.
The activity of UDP-glucose dehydrogenase was confirmed spectrophotometrically, on the basis of a method described previously (Ordman and Kirkwood, 1977) , by monitoring the formation of NADH. The reaction mixture consisted of Tris-HCl (50 mM, pH 8.7) with UDP-glucose dehydrogenase (0.28 units/ml), UDP-glucose (1 mM), dithiothreitol (5 mM), and NADϩ (2 mM) in a final volume of 200 l. Incubations were conducted in Polyfiltronics UVMax 96-well microplates (Whatman, Clifton, NJ), and the increase in absorbance at 340 nm was monitored using a Molecular Devices SpectraMax M2e plate reader (Molecular Devices, Sunnyvale, CA). Control incubations omitted either substrate or NADϩ.
The glycolytic activity of subcellular fractions and ␤-glucosidase was confirmed spectrophotometrically, on the basis of a method described previously (Berrin et al., 2002) , by monitoring the cleavage of 4-nitrophenyl ␤-D-glucopyranoside. The reaction mixture consisted of potassium phosphate buffer (50 mM, pH 5.5) and purified enzyme (0.5 units/ml) or pooled human liver subcellular fractions (0.5 mg/ml) in a final volume of 200 l. Incubations were conducted in Polyfiltronics UVMax 96-well microplates (Whatman), and the increase in absorbance at 400 nm was monitored using a Molecular Devices SpectraMax M2e plate reader (Molecular Devices).
Monolayer Efflux Studies. The polarized Madin-Darby canine kidney II (MDCKII) cells heterologously expressing human Pgp [MDCKII-multidrug resistance 1 (MDR1) cell line] were used for the in vitro transport studies and were obtained from The Netherlands Cancer Institute (Amsterdam, The Netherlands). Cell culture and transport studies were completed as described previously (Polli et al., 2008 N-[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl) (B 3 A) ]. Drugs were quantified by liquid scintillation counting using a Tri-Carb T2900 liquid scintillation counter and Ultima Gold scintillation cocktail (PerkinElmer Life and Analytical Sciences). For monolayer efflux studies, the flux of test articles and probe substrates was calculated using the following equation:
), V is the receptor volume (ml), C is the receiver drug concentration (nmol/ml), t is time in hours, and A is the membrane surface area (cm 2 ). The passive permeability of test articles, positive control substrates, and Lucifer yellow in the presence of GF120918 was determined using the following equation as described previously (Rautio et al., 2006) :
where P 7.4 is the permeability coefficient at pH 7.4, V D and V R are donor and receiver well volumes, respectively (ml), A is the membrane surface area (cm 2 ), t is the incubation time (seconds), C R (t) is the measured concentration in the receiver well at time t (nmol/ml), and C D (t) is the measured concentration in the donor well at time t (nmol/ml).
Results
Pharmacokinetics of Total Radioactivity, Remogliflozin Etabonate, Remogliflozin, GSK279782, and GSK333081 in Humans.
Eight fasted healthy male subjects received a single oral dose of 400 mg of [ 14 C]remogliflozin etabonate (mean dose of 402 Ϯ 1.0 mg/ 106 Ϯ 0.3 Ci). The pharmacokinetic parameters for total radioactivity, remogliflozin etabonate, remogliflozin, and GSK279782 (Ndealkylation; a pharmacologically active metabolite of remogliflozin) and GSK333081 (O-dealkylation; a metabolite of remogliflozin) are presented in Table 1 , and the corresponding plasma concentrationtime profiles are presented in Fig. 2 . Remogliflozin etabonate is rapidly absorbed (t max 0.5 h; t 1/2 0.39 h) and converted to remogliflozin (t max 0.64 h; t 1/2 1.57 h), followed by the formation of GSK279782 (t max 1 h; t 1/2 2.68 h) and GSK333081 (t max 1 h; t 1/2 2.84 h). Peak blood and plasma concentrations of total radioactivity occur at approximately 1 h after dosing. The rank order of the C max and AUC (0-ϱ) for the analytes from highest to lowest is total radioactivity remogliflozin Ͼ GSK279782 Ͼ Ͼ GSK333081 Ͼ Ͼ remogliflozin etabonate (Table 1) . The AUC (0-ϱ) of plasma radioactivity is approximately 14-fold higher than the sum of the AUC (0-ϱ) of remogliflozin etabonate, remogliflozin, GSK279782, and GSK333081, indicating the presence of significant additional circulating metabolites. Total radioactivity is eliminated from blood and plasma with half-
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at ASPET Journals on August 27, 2017 dmd.aspetjournals.org lives of 5.90 and 6.57 h, respectively, consistent with the metabolites following their own kinetics. The blood/plasma ratios for the total radioactivity C max and AUC (0-ϱ) are 0.64 and 0.61, respectively, indicating that drug-related material does not partition extensively into blood cells (Ͻ20%).
Absorption and Excretion of Radioactivity. The excretion of radioactivity in urine and feces is summarized in Table 2 . The mean total recovery of radioactivity was 95.4 Ϯ 2.03% through 144 h after dosing, with a mean of 92.8% recovered in the urine and 2.58% recovered in the feces. Elimination was rapid, with 92.0% of the dose recovered in the urine within 48 h after dosing. These results indicate that there was essentially complete absorption of the 14 C-radiolabeled dose. However, the overall bioavailability of remogliflozin from remogliflozin etabonate is low, on the basis of the observed extensive metabolism.
Metabolite Profiles. [ 14 C]Remogliflozin etabonate was stable in plasma and urine as determined by radiochemical profiles of control matrices spiked with the dosing solution. In contrast, [
14 C]remogliflozin etabonate was extensively degraded in extracts of spiked fecal homogenates under the Ϫ70°C or lower storage conditions; therefore, individual fecal profiles were not determined. However, because Ͼ90% of the radiolabel was excreted in the urine, the absence of fecal profiling does not alter the understanding of remogliflozin etabonate metabolism.
Plasma. Metabolite profiles of plasma pooled across subjects at 1, 4, 12, and 24 h after dosing are shown in Fig. 3 ; note the different y-axis scales for each plot. Drug-related material was quantified only in 1 and 4-h samples because the amount of radioactivity upon fractionation of the 12 and 24-h samples was low (Table 3 ). The major component at all time points was GSK1997711 (glucuronidation of the remogliflozin aglycone GSK1132678), which represented ϳ50% of the circulating radioactivity at 1 and 4 h. GSK1997714 (direct glucuronidation of remogliflozin) and GSK355993 (glucuronidation of the GSK279782 aglycone) represented ϳ6 to 18% of the total circulating radioactivity at 1 and 4 h, whereas remogliflozin and GSK279782 represented ϳ4 to 11%. Remogliflozin etabonate (ϳ115 min) and GSK333081 (ϳ71 min) are estimated to be Ͻ1% of the total circulating radioactivity.
Urine. Metabolite profiles of urine pools collected from 0 to 48 h (Fig. 4) were similar to 1 and 4-h plasma profiles. The most abundant metabolite in urine was GSK1997711, which represented 47.8% of the administered dose (Table 4) . M13 (glucuronidation of the GSK333081 aglycone), GSK355993, and GSK1997714 each represented ϳ6 to 13% of the dose. Remogliflozin and GSK279782 represented 7.9 and 3.4% of the dose, respectively. GSK333081 was also identified in urine but was below quantifiable limits. Two uncharacterized metabolites, representing Ͻ1% of the dose each, were also present. The total recovery of radioactivity was 95.4%.
Identification of the Pathway of GSK1997711 Formation. GSK1997711, the glucuronide conjugate of the remogliflozin aglycone, is the major circulating human metabolite, representing ϳ50% of the total circulating radioactivity. GSK1997711 could potentially be formed either directly from oxidation of the C6 hydroxyl of the glucose group by UDP-glucose dehydrogenase or indirectly through glucuronidation of the remogliflozin aglycone, GSK1132678 (Fig. 1) . In vitro studies demonstrated that GSK1997711 is produced only after [ 14 C]remogliflozin is first incubated with ␤-glucosidase to form GSK1132678 before incubation with HLM supplemented with glucuronidation reagents (Fig. 5) . In contrast, GSK1997711 is not formed directly from [ 14 C]remogliflozin when incubated with either purified UDP-glucose dehydrogenase or liver fractions (S9, cytosol), even though the activity of UDP-glucose dehydrogenase was confirmed spectrophotometrically by monitoring the formation of NADH (Ordman and Kirkwood, 1977 Sampling of blood and plasma for total radioactivity and specific analytes was done through 48 h. Concentrations of radioactivity were below limits of quantitation (125 and 119 ng Eq/ml for blood and plasma, respectively) by 36 h in all subjects. The mean percentage of the AUC (0-ϱ) extrapolated for total radioactivity and individual analytes was equal to or lower than 10%. C͔remogliflozin etabonate ͓mean, 402 Ϯ 1.0 mg (106 Ϯ 0.3 Ci)͔ by mouth administered as three capsules. The mean percentage of the AUC (0-ϱ) extrapolated for total radioactivity and individual analytes was equal to or lower than 10%.
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at ASPET Journals on August 27, 2017 dmd.aspetjournals.org across the MDCKII-MDR1 monolayers are 76 and 17, respectively, and decreased to 0.88 and 0.98, respectively, in the presence of GF120918 (Table 5) , consistent with these compounds being substrates for Pgp. The in vitro passive membrane permeability values of [ 14 C]remogliflozin etabonate and remogliflozin are 286 and 19 nm/s (P 7.4 B 3 A ϩ GF120918), respectively.
Identification of P450 Enzymes Involved in the Metabolism of Remogliflozin.
To further understand the metabolism of remogliflozin and to assess the potential for drug interactions, a P450 phenotyping study was completed. Remogliflozin etabonate was not studied because it is unstable in HLM in the presence or absence of NADPH as the prodrug is hydrolyzed readily by esterases under these   FIG. 3. HPLC-radiochromatogram of plasma extracts at 1, 4, 12 , and 24 h after a single 400-mg oral administration of [ conditions (half-life Ͻ 10 min). In contrast, remogliflozin is much more stable in HLM than remogliflozin etabonate. Incubation of 50 M [ 14 C]remogliflozin with HLM resulted in the formation of GSK279782, GSK333081, and two oxidative metabolites, M20 and a metabolite (molecular weight, 466) where the location of the oxidation is most likely on a methyl group from either of the isopropyl moieties (Fig. 6) . Formation of these metabolites is substantially impaired upon coincubation with azamulin, a selective CYP3A4 inhibitor (Stresser et al., 2004) . These four metabolites are also formed when [
14 C]remogliflozin is incubated with human recombinant CYP3A4, CYP2C9, or CYP2C19. Unlike azamulin, which extensively inhibited the formation of the four metabolites, sulfaphenazole (a selective CYP2C9 inhibitor) and benzylnirvanol (a selective CYP2C19 inhibitor) (Baldwin et al., 1995; Suzuki et al., 2002) only significantly inhibited the formation of the M20 oxidative metabolite, suggesting that CYP3A4 was the major P450 contributing to the metabolism of remogliflozin.
Effect of Ketoconazole on the Pharmacokinetics of Remogliflozin Etabonate, Remogliflozin, and GSK279782. To determine the quantitative role of CYP3A4 in the metabolism of remogliflozin, a clinical drug interaction study with ketoconazole was completed. Pharmacokinetic parameter estimates for remogliflozin etabonate, remogliflozin, GSK279782, and GSK333081 in the absence and presence of ketoconazole are summarized in Table 6 . The mean plasma exposure to remogliflozin etabonate and remogliflozin increased modestly upon coadministration with ketoconazole, yielding increases of 24, 30, and 33%, respectively, in the C max , AUC (0-ϱ) , and t 1/2 estimates of remogliflozin etabonate, and 32, 75, and 53%, respectively, in C max , AUC (0-ϱ) , and t 1/2 estimates of remogliflozin. In contrast, the plasma exposure to the metabolites decreased slightly for GSK279782 and substantially for GSK333081, resulting in 28 and 16% reductions, respectively, in C max and AUC (0-ϱ) of GSK279782 and 71 and 66% reductions, respectively, in C max and AUC (0-ϱ) of GSK333081. The metabolite-to-parent AUC (0-ϱ) ratio for remogliflozin to remogliflozin etabonate increased by approximately 33% after remogliflozin etabonate was coadministered with ketoconazole. In contrast, the mean metabolite-to-parent AUC (0-ϱ) ratio for GSK279782 to remogliflozin decreased by 52%, whereas that for GSK333081 decreased by 81%.
Discussion
SGLT2 inhibitors are a new class of potential antidiabetes drugs (Asano et al., 2004; Isaji, 2007; Bays, 2009; Idris and Donnelly, 2009) . Remogliflozin etabonate, the prodrug of remogliflozin, is a novel member of the ␤-D-glucopyranoside class of SGLT2 inhibitors. Like other members of this class, remogliflozin was developed as a prodrug to enhance oral absorption and reduce the susceptibility to glycosidase degradation (Ellsworth et al., 2008; Washburn, 2009) . Remogliflozin is the active entity with an in vitro IC 50 value of 12.4 nM (Fujimori et al., 2008) . To better understand the absorption, metabolism, and disposition of remogliflozin etabonate and risk for drug interactions, a series of in vitro and clinical studies were completed. The disposition of remogliflozin etabonate in humans was characterized in a mass balance study where eight healthy male volunteers each received a single 400-mg oral dose of [
14 C]remogliflozin etabonate. In addition, the importance of P450 enzymes and Pgp transport in remogliflozin etabonate and remogliflozin disposition was determined through in vitro studies and a ketoconazole clinical drug interaction study.
Remogliflozin etabonate is rapidly absorbed and metabolized to remogliflozin and a number of metabolites after oral dosing, with a median t max Յ 1 h for both remogliflozin etabonate and remogliflozin. Elimination of remogliflozin etabonate and remogliflozin from blood is rapid, with half-lives of 0.39 and 1.57 h, respectively. GSK279782 and GSK333081 are two metabolites in blood formed by N-and O-dealkylation of remogliflozin, respectively, and have slightly longer half-lives than remogliflozin (Table 1) . The AUC (0-ϱ) of plasma radioactivity is approximately 14-fold higher than the sum of the mean AUC (0-ϱ) of remogliflozin etabonate, remogliflozin, GSK279782, and GSK333081. In addition, the half-life of total radioactivity is longer (6.57 h) than the half-lives of these analytes. These data are consistent with the presence of significant additional circulating metabolites. Three glucuronide metabolites, GSK355993, GSK1997711, and GSK1997714, made up the majority of the circulating radioactivity detected in plasma, with GSK1997711 being the most abundant (48.9% of the radioactivity).
The products of remogliflozin metabolism are eliminated primarily via renal excretion, with 92.8% of the dose recovered in the urine. Similar to plasma, the glucuronide conjugates made up the majority of the metabolites identified in urine, with GSK1997711 accounting for Fig. 7 . The assessment of drug interactions is an essential activity in drug development. Results from the human mass balance study, along with in vitro and other clinical information, provide detailed mechanistic insights into the metabolic and transporter pathways involved in the drug's disposition. In vitro studies demonstrated that remogliflozin etabonate and remogliflozin are Pgp substrates with high and low/ moderate permeability, respectively. On the basis of these data, the potential for drug interactions of remogliflozin etabonate coadministered with Pgp inhibitors was also considered. The human mass balance study demonstrated that after oral dosing in humans, the remogliflozin etabonate dose underwent complete oral absorption Ͼ90%) . This observation provides strong clinical evidence that efflux transporters such as Pgp and breast cancer resistance protein do not limit the intestinal absorption of remogliflozin etabonate, remogliflozin, or metabolites; this is consistent with remogliflozin etabonate being a Biopharmaceutics Drug Disposition Classification System class 1 drug displaying high permeability and solubility (GSK data on file; Benet et al., 2011) and with remogliflozin being a Biopharmaceutics Drug Disposition Classification System class III compound having low permeability and high solubility. However, remogliflozin has demonstrated low central nervous system penetration in the rat, which may be related to Pgp efflux at the blood-brain barrier, its low passive permeability, or other mechanisms (Polli et al., 2012) . This is not a concern in humans, because the potential for drug interactions with Pgp inhibitors at the blood-brain barrier is very small (Eyal et al., 2009) .
In vitro studies suggest that the formation of GSK279782 and GSK333081 appears to be mediated primarily by CYP3A4, as demonstrated by incubations of remogliflozin with HLM and recombinantly expressed P450s. This finding has been confirmed in a clinical study with ketoconazole, which showed a reduction in the AUC (0-ϱ) of GSK333081 (Ϫ66%) and a modest increase in remogliflozin exposure (75%), indicating that CYP3A4 is only a minor metabolic pathway; the fraction of remogliflozin metabolized by CYP3A4 is less than 50%. In contrast, only a small reduction in AUC (0-ϱ) of GSK279782 (Ϫ16%) was observed, suggesting an alternative enzyme(s) can produce this metabolite in vivo. In support of this observation, both CYP2C9 and CYP2C19 were demonstrated to produce GSK279782 through in vitro P450 phenotyping studies (Fig. 6) . Overall, the in vitro P450 phenotyping, human mass balance, and clinical ketoconazole data suggest that the risk of drug interactions with P450 inhibitors is low because of the multiple P450 and non-P450 pathways for remogliflozin clearance. The modest changes in remogliflozin exposure are not clinically significant, because remogliflozin etabonate has a large therapeutic window, as demonstrated in clinical studies up to 1000 mg b.i.d. Dobbins et al., 2012) . Therefore, these data suggest that remogliflozin etabonate can be administered with P450 inhibitors without dose adjustments.
GSK1997711, GSK355993, and M13 are glucuronide conjugates of the remogliflozin, GSK279782, and GSK333081 aglycones, respectively. Theoretically, these metabolites could be formed directly through the oxidation of the C6 hydroxyl of the glucose group or indirectly through glucuronidation of the aglycone. Glucuronic acid is generated intracellularly by UDP-glucose dehydrogenase, using UDPglucose as a substrate. A possible role for UDP-glucose dehydrogenase in the direct formation of GSK1997711 was investigated by incubating [
14 C]remogliflozin with purified UDP-glucose dehydrogenase, as well as with liver fractions. These studies demonstrated that GSK1997711 was not formed under these conditions by UDP-glucose dehydrogenase. However, when [ 14 C]remogliflozin was first incubated with ␤-glucosidase to produce the aglycone, followed by incubation with HLM supplemented with glucuronidation reagents, GSK1997711 was readily formed (Fig. 5B) . These results suggest that GSK1997711, as well as GSK355993 and M13, is formed indirectly through glucuronidation of the aglycone. From a clinical drug interaction perspective, the risk of inhibition of remogliflozin and GSK279782 conversion to their respective aglycones via glucosidase inhibition appears low, because these enzymes are abundant in a number of tissues, including the intestine and liver (Day et al., 1998 (Day et al., , 2000 .
As discussed previously, remogliflozin etabonate is rapidly absorbed and extensively metabolized in humans. It is also important to understand how the metabolism in humans compares with that in the nonclinical species used for safety evaluation. Overall, the biotransformation pathways were similar in the nonclinical species with some qualitative differences (GSK data on file). In mice and rats, remogliflozin etabonate was rapidly adsorbed and converted to remogliflozin and GSK279782, whereas in dogs, remogliflozin and remogliflozin etabonate are the predominant circulating active components. GSK279782 plasma concentrations are low in the dog, whereas GSK333081 plasma concentrations are low in both the dog and rodents. A number of glucuronide conjugates have been identified in the nonclinical species, including M13, GSK355993, and GSK1997711. GSK1997714 was not detected in either the rat or the dog and was present at only low levels in mouse bile (Ͻ1% of the dose); however, several glucoside-glucuronide conjugates that are positional isomers of GSK1997714 were characterized in the mouse and dog. Finally, the remogliflozin aglycone (GSK1132678), which is the step before formation of GSK1997711, is only readily quantifiable in dog microsomal incubations, plasma, and feces (GSK data on file).
Remogliflozin and GSK279782 are both potent SGLT2 inhibitors (in vitro K i values of ϳ7-12 nM) and account for the majority of the pharmacological activity in vivo. In contrast, GSK333081 has an in vitro potency 3-fold lower (K i of ϳ30 nM) and a 12-and 3-fold lower (0-ϱ) ] than that of remogliflozin and GSK279782; thus, it is not expected that GSK333081 contributes significantly to the pharmacological activity. The prodrug, remogliflozin etabonate, does not have any pharmacological activity and represents Ͻ2% of the remogliflozin exposure. The glucuronide metabolites, GSK1997711, GSK1997714, and GSK355993, do not inhibit the SGLT1 or 2 transporters (GSK, unpublished data). In summary, after a single dose of [ 14 C]remogliflozin etabonate, the radioactivity is rapidly and highly absorbed after a single oral dose to humans, and dose recovery in urine is nearly complete. Remogliflozin etabonate is rapidly and extensively metabolized to remogliflozin, GSK279782, and GSK333081, which in turn are converted to their respective aglycones. The aglycones are conjugated with glucuronic acid and make up the majority of drug-related material in both the plasma and urine. These data suggest that remogliflozin etabonate has a low risk of drug interactions because of the multiple metabolic clearance pathways that include both P450 and non-P450 pathways. For AUC, C max , and t 1/2 , values are point estimates (90% CI) of the geometric least-square mean ratio between treatments on the basis of analysis of variance; and for t max , values are point estimates (90% CI) of the median difference between treatments on the basis of the Hodges-Lehmann method (Hauschke et al., 1990 Values are geometric mean (%CVb) for each parameter, except for t max , which are given as median (range). Unless stated otherwise, data from all 20 subjects were used in determining the pharmacokinetic parameter estimate. 
